Robert W Damon

US Patent:

7700637, Apr 20, 2010

Filed:

Sep 16, 2004

Appl. No.:

10/570338

Inventors:

Robert Edson Damon - Hopkinton MA, US
Thalaththani Ralalage Vedananda - Shrewsbury MA, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/42
C07D 263/30

US Classification:

514374, 548235

Abstract:

Compounds of the formula.

US Patent:

8394858, Mar 12, 2013

Filed:

Nov 30, 2010

Appl. No.:

12/956146

Inventors:

David Barnes - Waban MA, US
Gregory Raymond Bebernitz - Stow MA, US
Scott Louis Cohen - Peabody MA, US
Robert Edson Damon - Hopkinton MA, US
Robert Francis Day - Watertown MA, US
Monish Jain - Belmont MA, US
Rajeshri Ganesh Karki - Somerville MA, US
Louise Clare Kirman - Swampscott MA, US
Tajesh Jayprakash Patel - Medford MA, US
Brian Kenneth Raymer - Holliston MA, US
Herbert Franz Schuster - Ashland MA, US
Wei Zhang - Somerville MA, US

Assignee:

Novartis AG - Basel

International Classification:

A01N 37/18
A61K 31/16
C07C 327/48

US Classification:

514599, 564 74

Abstract:

The present invention provides a compound of formula I;.

US Patent:

20080293782, Nov 27, 2008

Filed:

Dec 6, 2006

Appl. No.:

12/096421

Inventors:

David Barnes - Waban MA, US
Gary Mark Coppola - Budd Lake NJ, US
Robert Edson Damon - Hopkinton MA, US
Katsumasa Nakajima - Winchester MA, US
Brian Christopher Raudenbush - Beacon Falls CT, US
Travis Stams - Stow MA, US
Sidney Wolf Topiol - Fair Lawn NJ, US
Thalaththani Ralalage Vedananda - Shrewsbury MA, US

International Classification:

A61K 31/433
C07D 285/10
A61P 3/10
A61P 3/04
A61P 9/10
A61P 25/28
A61P 35/00

US Classification:

514362, 548135

Abstract:

Compounds of the formulaare inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

US Patent:

20100152255, Jun 17, 2010

Filed:

Feb 26, 2010

Appl. No.:

12/713551

Inventors:

Robert Edson Damon - Cambridge MA, US
Thalaththani Ralalage Vedananda - Cambridge MA, US

International Classification:

A61K 31/421
A61K 31/196
A61K 31/426
A61K 31/357
A61P 3/00
A61P 3/06
A61P 9/10
A61P 9/00
A61P 9/12
A61P 3/04
A61P 29/00
A61P 19/02
A61P 35/00
A61P 25/28
A61P 11/00
A61P 17/00
A61P 27/02
A61P 1/00

US Classification:

514365, 514374, 514562, 514466

Abstract:

Compounds of the formulaprovide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

US Patent:

20120028969, Feb 2, 2012

Filed:

Jul 25, 2011

Appl. No.:

13/189760

Inventors:

David Weninger BARNES - Cambridge MA, US
Gregory Raymond BEBERNITZ - Cambridge MA, US
Kevin CLAIRMONT - Cambridge MA, US
Scott Louis COHEN - Cambridge MA, US
Robert Edson DAMON - Cambridge MA, US
Robert Francis DAY - Cambridge MA, US
Stephanie Kay DODD - Cambridge MA, US
Christoph GAUL - Basel, CH
Hatice Belgin GULGEZE EFTHYMIOU - Cambridge MA, US
Monish JAIN - Cambridge MA, US
Rajeshri Ganesh KARKI - Cambridge MA, US
Louise Clare KIRMAN - Cambridge MA, US
Kai LIN - Cambridge MA, US
Justin Yik Ching MAO - Cambridge MA, US
Tajesh Jayprakash PATEL - Cambridge MA, US
Brian Kenneth RAYMER - Cambridge MA, US
Liansheng SU - Cambridge MA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 31/542
A61K 31/5365
A61K 31/5377
A61K 31/4985
A61K 31/47
A61K 31/4245
A61K 31/4184
A61K 31/405
C07D 513/04
C07D 498/04
C07D 413/12
C07D 471/04
C07D 215/00
C07D 235/04
C07D 209/04
A61P 31/12
A61P 3/10
A61P 3/08
A61P 3/04
A61P 3/06
A61P 3/00
C12N 9/99

US Classification:

5142242, 435184, 5142305, 5142352, 514249, 514311, 514364, 514394, 514415, 544 48, 544105, 544144, 544350, 546152, 548143, 5483044, 548469

Abstract:

The present invention provides compounds of formula (I);or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.